Meeting
2016 ASCO Annual Meeting
Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy.
Authors
Andrea Wang-Gillam
Siteman Cancer Center, Washington University, Saint Louis, MO
Andrea Wang-Gillam , Chung-Pin Li , Gyorgy Bodoky , Andrew Dean , Yang-Shen Shan , Gayle S. Jameson , Teresa Macarulla , Kyung-Hun Lee , David Cunningham , Jean-Frédéric Blanc , Richard Hubner , Chang-Fang Chiu , Gilberto Schwartsmann , Jens T Siveke , Fadi S. Braiteh , Victor M. Moyo , Bruce Belanger , Eliel Bayever , Daniel D. Von Hoff , Li-Tzong Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT01494506
Citation
J Clin Oncol 34, 2016 (suppl; abstr 4126)
DOI
10.1200/JCO.2016.34.15_suppl.4126
Abstract #
4126
Poster Bd #
118
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.
First Author: Andrea Wang-Gillam
Poster
2023 ASCO Annual Meeting
FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC).
First Author: Benedikt Westphalen
Poster
2020 ASCO Virtual Scientific Program
A randomized phase II study of second-line treatment with liposomal irinotecan, and S-1 versus liposomal irinotecan and 5-fluorouracil in gemcitabine-refractory metastatic pancreatic cancer patients.
First Author: Esther Pijnappel
Poster
2020 ASCO Virtual Scientific Program
NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan + 5‑fluorouracil/leucovorin + oxaliplatin versus nab-paclitaxel + gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
First Author: Zev A. Wainberg